Author Archive: Daniel Seaton

Daniel Seaton

Daniel Seaton is BIO's Director for Health Communications, where he handles communications on public policy issues affecting members of BIO's health and emerging company sections. Prior to joining BIO in August 2013, he spent four years in communications at the Pharmaceutical Research and Manufacturers of America. The best part of his job is educating audiences about the many benefits the bioscience industry produces for patients, consumers, and the economy as a whole. Daniel enjoys hiking, camping, and, when he can find a game, playing bridge. Having grown up in New Mexico, one of his favorite foods is roasted green chile. He has a Master's degree in Public Relations and Corporate Communications from Georgetown University.

Latest Posts

Washington Post: Gene Therapies Offer “Dramatic Promise”


Yesterday’s Washington Post has an in-depth article about gene therapy, a type of therapeutic intervention which alters the underlying DNA responsible for producing certain diseases. The technology is enjoying a resurgence, fueled by some stunningly positive results in certain clinical trials recently. The authors begin with the story of 23 year old Allison Corona, who suffers from a congenital diseases that left her legally blind at age four. After receiving a gene therapy treatment: The world Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , ,

A National Blueprint for Biodefense Released Today


A major report was released today detailing findings and recommendations to improve the U.S. biodefense readiness. “A National Blueprint for Biodefense: Leadership and Major Reform Needed to Optimize Efforts” was authored by the Blue Ribbon Study Panel on Biodefense, on which BIO President and CEO Jim Greenwood serves. The panel is co-chaired by former Sen. Joe Lieberman and former Gov. Tom Ridge. Other panelists include former Secretary of Health and Human Services Donna Shalala, former Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: ,

Biotech Policy Outlook at #BIF15: 21st Century Cures, IPR, TPP, and PDUFA VI

BIO Investor Forum

To even the most casual observer, 2015 has been a big year in the biotech industry, particularly in Congress and in other venues wherein public policies that affect the sector take shape. Given the importance of the policy environment in determining how successful companies in our industry can be at delivering new cures and treatments to patients – and a return to the investors who finance their activities – we decided that a close look Read More >

Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO Investor Forum’s Impressive Program Lineup

BIO Investor Forum

This week, BIO announced the final program and speakers for the 14th Annual BIO Investor Forum, an international investor forum which explores investment trends and opportunities in life sciences.  The event focuses on early and mid-stage private as well as emerging public companies that are poised for growth in 2016. The event will take place October 20-21, 2015, at the Parc 55 in San Francisco, California. “This year’s BIO Investor Forum features a compelling and Read More >

Events  |  Leave a comment  |  Email This Post

Wall Street Journal: The Assault on Drug Innovation


Today, the Wall Street Journal published an editorial commenting on yesterday’s proposed plan by Secretary Hillary Clinton’s campaign to dramatically increase intrusive government regulation of our industry. BIO shared many of the concerns raised by this editorial, concerns which were noted in our statement yesterday. To put into perspective the potential consequences of that proposal, the editorial noted as an example that “Inside of a decade or two, metastatic cancer may become a chronic condition and chemotherapy a relic.” Breakthroughs Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , ,